Aqueous humor biomarkers in ocular oncology: Insights and advances.
Publication/Presentation Date
11-18-2025
Abstract
Ocular malignancies, though relatively rare, pose significant risks to patients' vision, quality of life, and potential for developing metastatic disease. Due to the eye's complicated and delicate anatomy, diagnosing ocular malignancy and monitoring its progression can be technically challenging. Current approaches include direct tumor biopsy, vitreous humor sampling, and imaging. However, these techniques are associated with rare, yet potentially severe, side effects and can be invasive or limited in detecting microscopic disease. Recent studies have introduced aqueous humor sampling as a promising, minimally invasive alternative to diagnose ocular malignancy, guide therapeutic management, monitor response to treatment, and track early recurrence. As oncologic biomarker research continues to progress, incorporating aqueous humor sampling into clinical practice may refine diagnosis, risk stratification, and therapeutic approaches to enhance patient outcomes. This article reviews the latest advances in aqueous humor biomarkers in common ocular malignancies, including uveal melanoma, intraocular lymphoma, and retinoblastoma.
Volume
6
Issue
11
First Page
102447
Last Page
102447
ISSN
2666-3791
Published In/Presented At
Cheslow, L., Caksa, S., Cain, R. E., Waldman, S. A., & Aplin, A. E. (2025). Aqueous humor biomarkers in ocular oncology: Insights and advances. Cell reports. Medicine, 6(11), 102447. https://doi.org/10.1016/j.xcrm.2025.102447
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
41205591
Department(s)
Administration and Leadership
Document Type
Article